STERIS plc $STE Shares Bought by Forsta AP Fonden

Forsta AP Fonden lifted its stake in shares of STERIS plc (NYSE:STE) by 34.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,500 shares of the medical equipment provider’s stock after acquiring an additional 16,100 shares during the quarter. Forsta AP Fonden owned 0.06% of STERIS worth $15,014,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Ballentine Partners LLC purchased a new position in STERIS in the 1st quarter worth about $267,000. CWM LLC boosted its holdings in shares of STERIS by 42.1% in the first quarter. CWM LLC now owns 3,518 shares of the medical equipment provider’s stock worth $797,000 after buying an additional 1,042 shares during the period. Edgestream Partners L.P. increased its position in shares of STERIS by 36.0% in the first quarter. Edgestream Partners L.P. now owns 16,055 shares of the medical equipment provider’s stock worth $3,639,000 after acquiring an additional 4,251 shares in the last quarter. Apollon Wealth Management LLC increased its position in shares of STERIS by 3.9% in the first quarter. Apollon Wealth Management LLC now owns 2,588 shares of the medical equipment provider’s stock worth $587,000 after acquiring an additional 96 shares in the last quarter. Finally, Wealthfront Advisers LLC raised its holdings in shares of STERIS by 53.4% during the first quarter. Wealthfront Advisers LLC now owns 2,883 shares of the medical equipment provider’s stock valued at $653,000 after acquiring an additional 1,004 shares during the period. 94.69% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Daniel A. Carestio sold 159 shares of STERIS stock in a transaction on Monday, October 6th. The shares were sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the sale, the chief executive officer owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. The trade was a 0.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Renato Tamaro sold 3,204 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total transaction of $798,564.96. Following the transaction, the vice president directly owned 7,221 shares in the company, valued at $1,799,762.04. The trade was a 30.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.07% of the stock is currently owned by company insiders.

STERIS Price Performance

STE opened at $267.82 on Thursday. The stock has a fifty day moving average price of $245.36 and a 200 day moving average price of $239.86. The company has a current ratio of 2.22, a quick ratio of 1.53 and a debt-to-equity ratio of 0.27. STERIS plc has a 1 year low of $200.98 and a 1 year high of $268.30. The stock has a market cap of $26.38 billion, a price-to-earnings ratio of 41.01 and a beta of 1.02.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.09. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same period in the previous year, the company earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Analysts forecast that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be issued a dividend of $0.63 per share. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 0.9%. STERIS’s dividend payout ratio (DPR) is currently 36.21%.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. KeyCorp raised their target price on STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 22nd. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Finally, Morgan Stanley upped their price target on STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and a consensus price target of $273.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.